Funding News Edition: December 19, 2018 See more articles in this edition
Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis and prognosis, as well as for developing precision therapeutics. NIAID is supporting this aim through a new tandem of funding opportunity announcements (FOAs)—Molecular and Genetic Characterization of Inborn Errors of Immunity (R01, Clinical Trial Not Allowed) and Molecular and Genetic Characterization of Inborn Errors of Immunity (R21, Clinical Trial Not Allowed).
Apply for funding if you wish to characterize genetic variants (coding or noncoding) that cause inborn errors of immunity or primary immunodeficiency diseases and elucidate the molecular, cellular, and immunological mechanisms of these disorders.
We strongly encourage research using state-of-the-art technologies and approaches.
You should finalize prioritization of putative disease-causing variants before applying. You should also delineate the functional consequences of the mutations under investigation using relevant cell types isolated from patients and appropriate controls.
Animal models are acceptable if they recapitulate the human disease; establish a clear correlation between the human and animal disease phenotypes in your application.
Note that clinical trials are not allowed. Read the FOAs for a list of other types of studies that NIAID considers nonresponsive, e.g., including targeted gene sequencing panels that will not aid in identifying novel disease-causing mutations.
For both FOAs, reference NIH’s standard Application Due Dates for deadlines.
The maximum project period for an R01 application is five years. For an R21 application, the project period cannot exceed two years.
The needs of your proposed project should determine your budget request, although R21 applications are capped at $275,000 for the full project period.
Read the FOAs linked above for complete details. Contact Dr. Frosso Voulgaropoulou, NIAID’s scientific/research contact for the FOAs, if you have any questions.